One thing many founders don’t realize is that presenting more assets to investors doesn’t always make a company more attractive. On paper, a broader portfolio appears to diversify risk and increase potential upside. However, the strongest investment theses are those where investors know exactly what they’re underwriting.
From an investor’s perspective, more is not always better.
As an early-stage company expands its product portfolio—drug candidates, indications, devices, or product features—each additional asset introduces another layer of complexity. Each asset may have its own technical risks, development timelines, capital requirements, and value inflection points.
Instead of evaluating one clear investment thesis, investors must evaluate several at once. The result is often a more difficult investment decision, greater execution risk, and less clarity about where the company’s value truly comes from.
If one asset is clearly the primary value driver, it often helps to make that asset the centerpiece of the investment story. The remaining assets should reinforce the long-term vision rather than compete for the investor’s attention. If management believes those assets deserve substantial standalone value, another approach may be to separate them into distinct companies or financing vehicles, allowing each opportunity to be evaluated on its own merits.
The founder’s job is to make the investment thesis obvious. Investors should leave the meeting knowing exactly what they are investing in, how to value it, and which milestones are most likely to create value. A singular focus makes the conversation much more effective.
Sometimes, less is more. A company doesn’t become more investable simply by adding more assets.
The observations shared in the From the ChaosBio Review Desk series are generalized lessons drawn from reviewing early-stage life sciences companies. Company identities, specific technologies, and other confidential details have been omitted or modified to protect confidentiality. The views expressed are my own and are intended solely for educational and discussion purposes.